Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in ...

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults ...

Amundi increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 42.9% in the fourth ...

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are presently covering the company ...

Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a ...

Stifel Nicolaus analyst Mathew Blackman maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for ...

In trading on Wednesday, shares of Tandem Diabetes Care Inc (Symbol: TNDM) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $19.16 per share.

In a report released yesterday, Matt Miksic from Barclays reiterated a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a ...

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and ...